ANGLE PLC Announces Partnership with Myriad Genetics for Parsortix System Development

ANGLE PLC has partnered with Myriad Genetics, a major diagnostics company, to develop a joint program for blood-based cancer testing. Myriad will cover development costs, providing ANGLE with revenue and future commercial opportunities. The partnership aims to enable blood-based alternatives to tissue biopsies, allowing for minimally invasive testing, earlier cancer detection, and repeat monitoring. ANGLE's long-term goal is widespread adoption of Parsortix across multiple tests and partners.

ANGLE PLC, a leading liquid biopsy company, has announced a strategic partnership with Myriad Genetics to develop a joint program for blood-based cancer testing. The collaboration aims to assess the feasibility of using circulating tumor cell (CTC) DNA from blood samples in conjunction with traditional tissue biopsies. This initiative could significantly enhance patient access to genomic information through a less invasive and potentially faster alternative to conventional biopsy procedures.

Under the agreement, ANGLE's research and development team will process blood samples from cancer patients using the Parsortix system to capture and harvest intact cancer cells for downstream molecular analysis. The results will be compared with matched patient tissue samples using Myriad's existing tissue-based assay. The collaboration is expected to broaden the use of liquid biopsy in precision oncology [1].

Andrew Newland, CEO of ANGLE, expressed his enthusiasm about the partnership, stating, "We are delighted to be working with Myriad Genetics, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system. This collaboration has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data" [2].

The financial terms of the agreement remain confidential, but the commercial potential is substantial. If successful, this collaboration could position ANGLE's technology as an integral component in Myriad's diagnostic workflow, potentially generating significant recurring revenue through either licensing arrangements or increased Parsortix system adoption. Additionally, Myriad will cover the development costs, providing ANGLE with revenue during the process and opening up major commercialization opportunities [3].

The partnership addresses a critical healthcare challenge: improving access to genomic data. Traditional tissue biopsies are invasive, costly, and sometimes impossible to obtain. A liquid biopsy alternative could dramatically expand patient access to precision medicine by offering a simpler, less invasive option that still provides actionable genomic information. This aligns with the growing trend toward minimally invasive diagnostic procedures.

While the collaboration is in its early stages, it signals a significant strategic positioning for ANGLE. The company's long-term goal is widespread adoption of Parsortix across multiple tests and partners, which could significantly broaden its market reach and support the widespread adoption of liquid biopsy testing in oncology.

References:
[1] https://pharmatimes.com/news/angle-partners-with-myriad-genetics-to-explore-blood-based-cancer-testing/
[2] https://www.ainvest.com/news/angle-partners-myriad-genetics-develop-invasive-cancer-treatment-approach-2508/
[3] https://www.proactiveinvestors.co.uk/companies/news/1077041/angle-ceo-on-breakthrough-liquid-biopsy-partnership-with-myriad-genetics-1077041.html